Brilinta Boost For AZ In Stroke Study
Outperforms Aspirin Alone In 11,000-Patient Trial
You may also be interested in...
Keeping Track: Kite’s Tecartus Is Third CAR-T With US FDA Approval; Submissions Round-Up
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
AZ’s Farxiga Gets FDA Priority Review For Heart Failure
AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.